Cryptococcosis Market is expected to reach a value of US$ 6.3 Billion by 2024: Transparency Market Research

The report on global cryptococcosis market has been classified on the basis of three categories treatment type, distribution channel, and geography (regions & countries). Major treatment segment included Amphotericin B, Flucytosine, Fluconazole, and Others (Voriconazole, surgery treatment, etc.). In terms of Amphotericin B the market divided into Amphocin, Fungizone, and Other Drugs. The report offers a detailed description behind the steady growth rate of the market and a possible growth trajectory at the global as well as regional level in terms of value and the market share for each cryptococcosis segment. The report is thus, compiled with the prime intent of updating the stakeholders with the incumbent market dynamics through a graphical illustration and in-depth analysis of each segment considered within the study scope.

The global Cryptococcosis Market was valued at US$ 4.1 Bn in 2015 and is estimated to reach US$ 6.3 Bn by 2024 at a CAGR of 4.8% from 2016 to 2024. 

The report on global cryptococcosis market has been classified on the basis of three categories treatment type, distribution channel, and geography (regions & countries). Major treatment segment included Amphotericin B, Flucytosine, Fluconazole, and Others (Voriconazole, surgery treatment, etc.). In terms of Amphotericin B the market divided into Amphocin, Fungizone, and Other Drugs. The report offers a detailed description behind the steady growth rate of the market and a possible growth trajectory at the global as well as regional level in terms of value and the market share for each cryptococcosis segment. The report is thus, compiled with the prime intent of updating the stakeholders with the incumbent market dynamics through a graphical illustration and in-depth analysis of each segment considered within the study scope.

Geographically, the report has been segmented into five regions: North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. These regions are further segmented into major national markets such as in North America (U.S. and Canada), Europe (U.K., Germany, Italy, Spain, France, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, and Rest of Asia), Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa) and Latin America (Brazil, Mexico, and Rest of Latin America).

North America leads the global cryptococcosis market commanding more than 44.1% share in the global cryptococcosis market in 2015. Recent advances in cryptococcosis diagnostics with biomarker test, reimbursement for disease screening, and improved access to antifungal drugs such as flucytosine are the major drivers of the cryptococcosis market in North America. U.S. is the major market in North America. The cryptococcosis market in the U.S. is driven by rising prevalence of cryptococcus gattii in the Pacific Northwest Region of the U.S. Moreover, major factors such as HIV population, highly structured health care industry, and availability of well-defined reimbursement policies from public and private health insurance firms fuel the growth of the cryptococcosis market in the U.S.

For more Information, Inquire for Report Sample – http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14984 

Middle East & Africa held the second largest share in 2015 with contribution of around 28.2% in 2015. Middle East & Africa is the second leading market due to the major contribution of Sub-Saharan countries where the burden of HIV related cryptococcosis infections are very high. Most of the drugs in the region are distributed by non-government organizations. However, the retail pharmacies segment held significant market share in Middle East & Africa. Amphotericin B is the largest segment in terms of revenue in the cryptococcosis market in Middle East & Africa. High penetration of amphotericin B due to awareness programs of various government and non-governmental institutes boosts the market in Middle East & Africa.

Asia Pacific is the third largest region in the global cryptococcosis market. Cryptococcosis infection is broadly distributed across Asia Pacific. However, it majorly occurs in countries such as Malaysia, India, Hong Kong, and China. High awareness about latest drugs available in the market, higher purchasing power, and affordability of drugs such as flucytosine are likely to boost the cryptococcosis market in Asia Pacific. Improvement in health care reforms in select countries of Asia Pacific, namely, India, Malaysia China, and Indonesia has enabled access to novel healthcare solutions and thus increased life expectancy of the population. Also, Asia is a relatively untapped market than the developed regions. Hence, the region presents better opportunity for growth in this market. Europe and Latin America are relatively minor market. In Latin America, Brazil is the key market which accounted for the largest share of the cryptococcosis market in Latin America.

Major players profiled in this report include Bristol-Myers Squibb Company, Janssen Biotech, Inc. (Johnson & Johnson), Abbott Laboratories, Novartis AG, Pfizer, Inc., Valeant Pharmaceuticals, Inc., Glenmark Pharmaceuticals and Sigmapharm Laboratories LLC. The global cryptococcosis market is fragmented with presence of few large and small scale generic drug manufacturing vendors that operates global market. However, the global market is dominated by few major players.

The global Cryptococcosis Market has been segmented as given below:

Global Cryptococcosis Market, by Treatment,

  • Amphotericin B
    • Amphocin
    • Fungizone
    • Other
  • Flucytosine
    • Ancobon
    • Other
  • Fluconazole
    • Diflucan
    • Other
  • Others (Voriconazole, surgery treatment, etc.)

Global Cryptococcosis Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Mail Order Pharmacies
  • Other

Global Cryptococcosis Market, by Region

  • North America
    • U.S.
    • Canada
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: 
sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

VN:F [1.9.22_1171]
Rating: 5.0/5 (1 vote cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)
Cryptococcosis Market is expected to reach a value of US$ 6.3 Billion by 2024: Transparency Market Research, 5.0 out of 5 based on 1 rating

No comments.

Leave a Reply

You must be logged in to post a comment.